Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $7.00.

INTS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. HC Wainwright raised their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th.

Intensity Therapeutics Price Performance

Intensity Therapeutics stock opened at $3.18 on Friday. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $3.87 and a 200 day moving average price of $4.32. Intensity Therapeutics has a 12-month low of $3.09 and a 12-month high of $43.50. The stock has a market cap of $10.38 million, a P/E ratio of -0.89 and a beta of 2.81.

Intensity Therapeutics (NASDAQ:INTS) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Sell-side analysts anticipate that Intensity Therapeutics will post -2.64 earnings per share for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors. The company’s approach is based on its proprietary INTASYL technology, which is intended to enable therapeutic compounds to enter tumor cells directly, promote cancer-cell death and stimulate an immune response against tumor tissue.

Intensity Therapeutics’ lead investigational product, INT230-6, is an intratumoral therapy formulated to deliver anticancer agents directly into tumors.